Researchers at UCLA have found a possible explanation for why autistic children act and think differently than their peers.
Shire announced positive results of a European Phase 3 study of once-daily lisdexamfetamine dimesylate in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.
Researchers announce findings that show the inhibition of both microRNA-33a and microRNA-33b with chemically modified anti-miR oligonucleotides suppress triglyceride levels and cause an increase in high density lipoprotein cholesterol.
Thermo Fisher Scientific Inc. introduced its Matrix Amber 2D barcoded tubes, expanding its sizeable sample storage product portfolio to offer protection of light-sensitive samples.
Supercritical Fluid Technologies, Inc.’s SFT-250 supercritical fluid extractor is designed to perform a variety of extractions in supercritical fluid and is engineered to meet the day-to-day rigors of the research lab.
Two independent groups from Massachusetts General Hospital and University of Houston College of Pharmacy used the T2MR platform to analyze whole blood specimens from patients with 5 different types of Candida spp. infections.
Sagent Pharmaceuticals, Inc. announced U.S. FDA approval of bupivacaine hydrochloride injection, USP, a local or regional anesthetic. Sagent's bupivacaine will be available in six single-dose and two multi-dose latex-free vials.
Merck announced results from a Phase 2b study evaluating the investigational use of Victrelis in combination with peginterferon alfa and ribavirin for the treatment of chronic HCV genotype 1 infection in adult patients coinfected with HIV-1.
Drugmaker Watson Pharmaceuticals Inc. said that the Food and Drug Administration has approved its testosterone patch Androderm in a smaller size and lower dose.
Hedge fund SAC Capital Advisors LP is being investigated by federal regulators for using inside information to profit from a health care takeover in 2009, the Wall Street Journal reported.
Amgen Inc., the world's largest biotech company by revenue, likely will focus on sales prospects for its top drugs and progress on its experimental drugs when it reports third-quarter results.
The European Union is investigating whether drug companies Novartis and Johnson & Johnson colluded to keep a generic painkiller out of the Dutch market, the bloc's antitrust watchdog said.
Starting HIV therapy in patients with both HIV and tuberculosis within two weeks of TB treatment increases survival by 33%.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced that the U.S. Food and Drug Administration has approved a new use for Byetta (exenatide) injection.